Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.7.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
12 Months Ended
Dec. 31, 2016
USD ($)
Number
shares
Dec. 31, 2015
USD ($)
shares
Number of operating segment | Number 1  
Number of reporting unit | Number 1  
Depreciation expense | $ $ 6,091 $ 6,749
Advertising costs | $ $ 45,400 $ 4,000
Stock Options [Member]    
Anti dilutive weighted average number of common shares 12,289,000 6,289,000
Warrant [Member]    
Anti dilutive weighted average number of common shares 28,424,669 12,424,669
Share [Member]    
Anti dilutive weighted average number of common shares 60,227,273 24,000,000
Advance Pharmaceutical Company [Member] | Revenue [Member]    
Concentration risk 53.00% 71.00%